GovChime
Notice ID: 0e2f545a1b5f41118bf8587aa5d5e61fSolicitationCancelled on SAM.gov

Naloxone Oral Syringes

Cancelled on SAM.gov (notice posted October 27, 2025). Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
3:00 PM MDT
Posted
October 27, 2025
Notice type
Solicitation
Set-aside
No Set aside used
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of WarDepartment of the Army

Notice details

Office
US ARMY MEDICAL COMMAND.W40M MRC0 WEST
Place of performance
JBSA Ft Sam Houston, Texas, 78234
Last updated
Nov 8, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
W81K00-26-Q-A022
Notice ID
0e2f545a1b5f41118bf8587aa5d5e61f

Description

THE PURPOSE OF SOLICITATION AMENDMENT 0002 IS TO EXTEND THE SOLICITATION TO 28 OCTOBER 2025 FOR THE NALOXONE 2MG/2ML ORAL SYRINGES.

The Department of Pharmacy at Brooke Army Medical Center (BAMC) is requesting a base plus 4 year (5 years total) contract for 1,413 Naloxone oral syringes annually.

Bidder Questions Due: 17 Oct 2025

Responses Due: 28 Oct 2025, 3:00 p.m., MST

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Secondary Contact

Documents

Files (5)

  • Solicitation Amendment - W81K0026QA0220001.pdf

    2.6 MBAdded in Solicitation version 4Posted
    Download
  • Combined Synopsis Solicitation.docx

    20 KBAdded in Solicitation version 4Posted
    Download
  • Brand Name Justification (Naloxone Oral Syringes) KO Signed._Redacted.pdf

    516 KBAdded in Solicitation version 4Posted
    Download
  • Solicitation Amendment - W81K0026QA0220002.pdf

    2.6 MBAdded in Solicitation version 4Posted
    Download
  • Questions and Answers_10SEPT25_Redacted.pdf

    884 KBAdded in Solicitation version 4Posted
    Download

Lifecycle

  1. 3
    Version 3Sources SoughtArchived

    Naloxone Oral Syringes

    Notice 44592470044c468587a13a6ca1f84b9b on SAM.gov

  2. 4
    Version 4SolicitationArchived

    Type changed from Sources Sought to Solicitation

    Naloxone Oral Syringes

    Notice 86da5e8e8f344dffb13336ebde7a09c3 on SAM.gov

  3. 5
    Version 5SolicitationCancelledArchivedCurrent

    Naloxone Oral Syringes

    Notice 0e2f545a1b5f41118bf8587aa5d5e61f on SAM.gov

Other notices for this solicitation

  1. Combined SynopsisRelated noticeSep 24, 2025

    Naloxone Oral Syringes

    Notice 51f92590e6714dc093bfd844094060e4 on SAM.gov

  2. Combined SynopsisRelated noticeOct 27, 2025

    Naloxone Oral Syringes

    Notice f98063e3f369470e81126474d06b8b67 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Request for Quote (RFQ): The Tennessee Army National Guard (TNARNG) Purchasing and Contracting Office for United States Property and Fiscal Office (USPFO) TN located at 3041 Sidco Drive, Nashville, TN 37204is issuing an RFQ for commercial single award contract in accordance with (IAW) the format in Federal Acquisition Regulations (FAR) subpart 12 as supplemented with additional information included in this notice. The North American Industry Classification System (NAICS)code for this requirement is 325412 Pharmaceutical Preparation Manufacturing. This documentation incorporates provisions and clauses that are in effect through the Federal Acquisition Circular (FAC) 2026-06 effective date 03/13/2026. The Government intends to award a single Firm Fixed Price contract. PLEASE SEE ATTACHED SOLICITATION FOR MORE INFORMATION.
66%
Combined Synopsis04/23/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 newly approved drugs will be reviewed: Atebrioz – Skeletal Muscle Relaxants and Combinations – Subclass: NA Emcitate – Thyroid and Antithyroid Agents – Subclass: NA Hibsago – Hepatitis B Agents – Subclass: NA Juvmo – Parkinsons Agents – Subclass: NA Zegfrovy – Lung Cancer – Subclass: EGFR+ NSCLC The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9102. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
64%
Solicitation11/30/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following February 2027 drug classes/subclasses will be reviewed: a. Ophthalmic - Dry Eye Cequa Eysuvis Miebo Tryptyr Tyrvaya Verkazia Vevye Xiidra b. Testosterone Replacement Therapy - Orals Jatenzo Kyzatrex Tlando The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-27-Q-9101. Pre-quotation teleconference is on November 17, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
64%
Solicitation12/07/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
64%
Solicitation10/26/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Awiqli Flextouch - Insulin - Basal b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors c. Lipfendra - Antilipidemics-1 - PCSK-9 d. Trutakna - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
64%
Solicitation08/27/2026

Additional Details

Solicitation Number

W81K00-26-Q-A022

Archive Date

Nov 12, 2025

Office Address

JBSA FT SAM HOUSTON, TX, 78234-4504